WO2015024217A1 - 一种绿原酸粉针剂及其制备方法 - Google Patents
一种绿原酸粉针剂及其制备方法 Download PDFInfo
- Publication number
- WO2015024217A1 WO2015024217A1 PCT/CN2013/081967 CN2013081967W WO2015024217A1 WO 2015024217 A1 WO2015024217 A1 WO 2015024217A1 CN 2013081967 W CN2013081967 W CN 2013081967W WO 2015024217 A1 WO2015024217 A1 WO 2015024217A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chlorogenic acid
- injection
- powder
- mannitol
- parts
- Prior art date
Links
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 title claims abstract description 157
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 title claims abstract description 157
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 title claims abstract description 157
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 title claims abstract description 157
- 235000001368 chlorogenic acid Nutrition 0.000 title claims abstract description 157
- 229940074393 chlorogenic acid Drugs 0.000 title claims abstract description 157
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 title claims abstract description 157
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 title claims abstract description 157
- 238000002347 injection Methods 0.000 title claims abstract description 76
- 239000007924 injection Substances 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 29
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 25
- 229930195725 Mannitol Natural products 0.000 claims description 25
- 239000000594 mannitol Substances 0.000 claims description 25
- 235000010355 mannitol Nutrition 0.000 claims description 25
- 238000004108 freeze drying Methods 0.000 claims description 24
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 23
- 235000006708 antioxidants Nutrition 0.000 claims description 23
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000005388 borosilicate glass Substances 0.000 claims description 10
- 229920005549 butyl rubber Polymers 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 238000007710 freezing Methods 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims description 6
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 6
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 6
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000005022 packaging material Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000000859 sublimation Methods 0.000 claims description 4
- 230000008022 sublimation Effects 0.000 claims description 4
- 238000012371 Aseptic Filling Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 229940001607 sodium bisulfite Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical group CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 claims 1
- 241001411320 Eriogonum inflatum Species 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 229940090044 injection Drugs 0.000 description 59
- 239000000243 solution Substances 0.000 description 22
- 229960001855 mannitol Drugs 0.000 description 20
- 238000001914 filtration Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 238000001179 sorption measurement Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000005352 clarification Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 239000012982 microporous membrane Substances 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 8
- 238000012216 screening Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000004883 caffeic acid Nutrition 0.000 description 4
- 229940074360 caffeic acid Drugs 0.000 description 4
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229940093181 glucose injection Drugs 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000004313 glare Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000011129 pharmaceutical packaging material Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 229930192334 Auxin Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical group [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates to a chlorogenic acid powder injection.
- Chlorogenic acid is a polyphenolic compound. Experimental studies have shown that it is unstable under acid, alkali, light and high temperature conditions. Zhou Hongqi, Olthof MR and Gonthir MP reported that chlorogenic acid is an unstable polyphenolic compound. Moreover, it is susceptible to factors such as digestive flora, and the bioavailability of oral administration is low, and it is preferable to use a blood vessel administration method, so that the injection dosage form is a better dosage form of the drug. Chlorogenic acid is unstable in aqueous solution, so it is not suitable to use a liquid dosage form.
- the technical solution of the present invention provides a chlorogenic acid powder injection, and another technical solution of the present invention provides a preparation method of the chlorogenic acid powder injection.
- the present invention provides a chlorogenic acid powder injection prepared from the following raw materials by weight ratio:
- the scaffolding agent is one or two of sucrose, mannitol, glucose, lactose, trehalose, hydroxyethyl starch, dextran 20, sorbitol, PEG1000, glycerin, glycine, 1, 2-propanediol More than one kind of mixing;
- the antioxidant is one or a mixture of two or more of sodium hydrogen sulfite, sodium metabisulfite, L-cysteine hydrochloride or vitamin C.
- the scaffolding agent is mannitol; and the antioxidant is sodium hydrogen sulfite.
- the invention also provides a method for preparing the powder injection, which comprises the following steps: a, weighing chlorogenic acid, sodium hydrogen sulfite, mannitol;
- the sulphuric acid is added in an amount of 0. 03% by weight of activated carbon, and the temperature is 45. After stirring for 30 minutes, the activated carbon was removed by filtration, and then filtered through a 0.20 um hydrophilic microporous membrane to the filtrate. Clarification, aseptic filling, lyophilization, that is.
- the lyophilization step is carried out by double-temperature lyophilization, pre-freezing at -38 ° C for 3 hours, the condenser temperature is -60 ° C, and the temperature rise time is -45 ° C to - 23 ° C. 12h, -23 °C ⁇ - 28 °C, the heating time is 6. 5h, the initial vacuum is 400 ⁇ 450 mbar, the end vacuum is 180 ⁇ 200 mbar, the minimum vacuum is 180 mbar, the sublimation drying time is 24 hours, and then drying 30 °C, 3h.
- the pH of the pH is 3 ⁇ 3.
- the packaging material is a brown borosilicate glass controlled injection bottle and a medicinal butyl rubber stopper.
- Chlorogenic acid is an unstable polyphenolic compound, and is susceptible to factors such as digestive flora, and adopts an injection type, and the drug has high bioavailability and rapid effect;
- the acid is unstable in aqueous solution, and the lyophilized powder dosage form can avoid the decomposition of chlorogenic acid in water.
- Rapid drug effect The injection is directly injected into the human tissue, so the absorption is fast and the effect is rapid. In particular, intravenous injection, which directly enters the blood vessel without an absorption phase, is the fastest in all dosage forms. 3.
- the dosage is accurate and the effect is reliable:
- the injection is a non-gastrointestinal route, which is not affected by various factors of the stomach and intestine, so the dosage is accurate and the effect is reliable. 4. Suitable for patients who cannot be orally administered.
- the chlorogenic acid powder injection of the invention has good stability, strong resolubility and safety in clinical use.
- Chlorogenic acid is a polyphenolic compound, which is easily oxidized. In the formulation study, whether or not to add antioxidants should be considered. The solubility of chlorogenic acid in water is about 2%, and the concentration should be 2% when the solution is prepared. Chlorogenic acid has hygroscopicity and should be controlled by formulation research and production environment humidity; chlorogenic acid is sensitive to light, and should be selected from materials that can be directly protected from light; chlorogenic acid is sensitive to heat, and the process should be handled. Temperature is controlled.
- Chlorogenic acid has a polyphenol structure and is easily decomposed by oxidation.
- antioxidants in the formulation of the formulation. 2%, intends to use the above several antioxidants, the commonly used antioxidants are sodium bisulfite, sodium metabisulfite, L-cysteine hydrochloride and vitamin C, etc., the usual amount is 0. 1 ⁇ 0. filter.
- the molecular structure of chlorogenic acid contains ester bonds, and PH has an important influence on the rate of hydrolysis and degradation.
- the pH value of the chlorogenic acid is adjusted by using a phosphate buffer solution at 1. 5 ⁇ 6. 2 , and the degradation rate constant k of the chlorogenic acid is measured, and the pH of the pH-degradation reaction rate curve is obtained by plotting lgk at each pH to P H . Determine a stable pH m value.
- the results are shown in Figure 1.
- the chlorogenic acid degradation was calculated according to the first-order kinetics. The results are shown in Table 1 ⁇ 2 and Figure 1.
- the scaffold is mainly used in freeze-dried injection. Its function is to ensure that the solid crystals are uniform after lyophilization, the color is consistent, the volume of the original liquid is basically kept, and it does not collapse, does not shrink, and has good dispersibility.
- Commonly used stenting agents include mannitol, lactose and glycine. It is intended to use different amounts of mannitol, lactose and glycine for prescription screening.
- L-cysteine hydrochloride 2580619 (100%) 2359955 (91. 4%) 2317304 (89. 8%) Vitamin C 2551027 ( 100%) 2299927 (90. 2%) 2255217 (88. 4%)
- the antioxidants sodium bisulfite, L-cysteine hydrochloride and vitamin C used in the experiment all increased the stability of chlorogenic acid. Sodium metabisulfite did not increase the stability of chlorogenic acid. However, L-cysteine was added. The chlorogenic acid solution of the hydrochloride and vitamin C was darkened, and the addition of sodium hydrogen sulfite had no effect on the color of the chlorogenic acid solution.
- sodium hydrogen sulfite as an antioxidant has a high standard potential (E°), which can replace oxidative damage in place of drugs.
- E° standard potential
- sodium bisulfite as an antioxidant has hemostasis. 1% ⁇ 0%. 2%.
- Sodium bisulfite is a commonly used antioxidant for injections. It has high safety to human body and is a reducing substance with chlorogenic acid. It does not react with each other and has good compatibility (test products) The influencing factors experiment also proves that the two have good compatibility), so choose 0. 1% sodium hydrogen sulfite as an antioxidant of this product.
- 4% mannitol was used as a scaffold to obtain a product with good formability, resolubility and clarity.
- Mannitol is a commonly used scaffold for lyophilized powder injection. It has high safety to human body, stable chemical properties, and is not easy to react with chlorogenic acid. Both should have good compatibility (the impact of pilot products)
- the factor experiment also proved that the two have good compatibility), so 4% mannitol was determined as the scaffold for this product.
- the prescription is determined by 1000 preparation units (30 mg/piece):
- test items were: traits , loss on drying, related substances and content.
- Chlorogenic acid plus auxiliary white powder 1. 67 0. 079 0. 106 0. 155 0. 203 0. 030 0. 494 99. 57 chlorogenic acid dark brown mass 2. 25 0. 104 0. 134 0. 160 0. 294 0. 039 0. 627 99. 36
- Chlorogenic acid plus auxiliary light brown powder 0. 52 0. 107 0. 125 0. 165 0. 261 0. 030 0. 580 99. 42 chlorogenic acid dark brown mass 2. 13 0. 121 0. 143 0. 175 0. 306 0. 047 0. 670 99. 31 chlorogenic acid plus auxiliary light brown powder 0. 60 0. 116 0. 128 0. 164 0. 258 0. 034 0. 584 99. 41
- the result is high temperature for 5 days and Compared with 0 days, the chlorogenic acid and chlorogenic acid supplements were basically the same in terms of traits, loss on drying, related substances and chlorogenic acid content, indicating that the excipients and chlorogenic acid were higher under high temperature (6CTC) conditions. Good compatibility.
- Chlorogenic acid plus auxiliary white powder 1. 67 0. 079 0. 106 0. 155 0. 203 0. 030 0. 494 99. 57 chlorogenic acid yellowish mass 4. 22 0. 102 0. 123 0. 157 0. 203 0. 036 0. 518 99. 47
- Chlorogenic acid plus auxiliary light brown powder 0. 63 0. 112 0. 127 0. 495 0. 232 0. 042 0. 896 99. 10 Results glare exposure 5 days and 10 days compared with 0 days, chlorogenic acid and The changes of chlorogenic acid and auxiliary materials in terms of traits, loss on drying, related substances and chlorogenic acid content were basically the same, indicating that the auxin has good compatibility with chlorogenic acid under strong light irradiation conditions.
- the process of chlorogenic acid for injection is designed as: liquid distribution ⁇ sterilization filtration ⁇ aseptic filling ⁇ freeze drying ⁇ Packaging, production process flow chart shown in Figure 2.
- the order of feeding is to first add an antioxidant sodium hydrogen sulfite, dissolve it with water for injection, then add chlorogenic acid to dissolve, and finally add the scaffold mannitol to stir and dissolve.
- the solubility of chlorogenic acid in water is about 2%, the concentration of the solution (about 1.5%) is less than the solubility, and it should be fully dissolved under normal temperature conditions, and it is verified that it can be completely dissolved at the concentration of the solution.
- Activated carbon is a commonly used adsorbent for the preparation of injections. There are many micropores inside the particles, which have a large active surface and adsorb the pigment, impurities and heat of the liquid. The amount of the activated carbon is 0. 02 ⁇ 0. 04%; the amount of the activated carbon is 0. 02 ⁇ 0. 04%; 5% ⁇ The mannitol. In order to fully ensure the safety of the preparation, the activated carbon is used to adsorb the pigment, impurities and heat source in the liquid, but the more the activated carbon is added, the greater the adsorption and the loss of chlorogenic acid, so the amount of activated carbon is screened. Table 8.
- the adsorption time of activated carbon is 30 minutes, and the temperature of water for injection is 45 ⁇ 50° (:.
- the bacterial endotoxin test of small-scale test products and pilot products proves that this step can effectively remove pyrogens.
- the filter paper is initially filtered to remove activated carbon. The solution was verified to be clear after initial filtration.
- Chlorogenic acid is sensitive to heat.
- the fine filtration process is used to remove and remove the final product.
- Fine filtration often uses 0. 22 ⁇ microporous membrane, this product is an aqueous solution, so the hydrophilic filtration process is carried out using a hydrophilic 0.22 ⁇ microporous membrane.
- the filtration membrane integrity is used as an indicator in the fine filtration process. Reliability; The adsorption rate of chlorogenic acid by the filter after fine filtration is used to investigate the adsorption of chlorogenic acid by the filter; the sterility check, clarity and color and visible foreign matter of the finely filtered liquid are used as indicators. , to investigate the feasibility of the fine filtration process.
- the foaming point pressure of the filter film before the fine filtration was 0. 40Mpa, fine filtration, was carried out with a hydrophilicity of 0.22 ⁇ m microporous membrane (Shanghai Yadong Nuclear Resin Co., Ltd.).
- the pressure point of the filter is 0. 41Mpa, and has good integrity before and after fine filtration, indicating that the microporous membrane is suitable for sterilization and impurity removal of chlorogenic acid for injection.
- Chlorogenic acid content before filtration (mg/ml) Chlorogenic acid content after filtration (mg/ml) Adsorption rate (%)
- the hydrophilic membrane is 0.22 ⁇ microporous membrane (Shanghai Yadong Nuclear Resin Co., Ltd.) Division) for fine filtration, can effectively remove bacteria and foreign matter in the liquid, while the loss of chlorogenic acid is small.
- Chlorogenic acid is sensitive to heat, so it is produced by freeze-drying process. Chlorogenic acid is relatively stable under low temperature conditions, the solid content of the liquid is not high, the viscosity is low, and it is easy to freeze-dry and form. Therefore, the freeze-drying process is studied by conventional freeze-drying conditions.
- the frozen intervention test conditions were pre-freezing temperature -38 ° C, pre-freezing time 3 hours, condenser temperature -60 ° C, sublimation drying time 24 hours.
- Dry weight loss 2.86% freeze-drying process pre-test results show that under this condition, the appearance, resolubility and loss on drying of the lyophilized sample are good, so the pre-freezing temperature of the product is determined to be -38 °C, pre- The freezing time was 3 hours, the condenser temperature was -60 ° C, the initial vacuum was 400 to 450 mbar, the end vacuum was 180 to 200 mbar, the minimum vacuum was 180 mbar, and the sublimation drying time was 24 hours.
- the freeze-drying curve reflects the relationship between the material temperature, the separator temperature, the condenser temperature, and the vacuum of the chamber over time during the freeze-drying process.
- the drawing of the freeze-drying curve not only reflects the performance of the freeze dryer, but also has certain guiding significance for actual production, as shown in Figure 4.
- the production process of chlorogenic acid for injection is determined as follows: According to the prescription of the preparation, the process is verified by 125 batches, and the water for injection is taken, and sodium hydrogen sulfite, chlorogenic acid and mannitol are sequentially added, and the mixture is fully stirred. Dissolved, the pH is controlled at 2 ⁇ 4; 0. 03% needle is added with activated carbon, stirred for 30 minutes, filtered to remove activated carbon, and then finely filtered with 0.22 ⁇ microporous membrane to clear the filtrate, aseptically filled, as determined by freezing The dry process parameters are lyophilized and the cap is obtained.
- Chlorogenic acid is sensitive to light. It should be selected from direct contact with pharmaceutical packaging materials. Therefore, brown low borosilicate glass controlled injection bottles and medicinal butyl rubber stoppers are preliminarily determined as packaging materials for direct contact with pharmaceuticals.
- the chlorogenic acid for injection was placed in a 6 CTC incubator, with a relative humidity of 92.5%, 25 ° C incubator and illumination (4500 ⁇ 500) lx.
- the instrument was taken out in 5 and 10 days to test the appearance of the preparation. Traits, solution color, pH, insoluble particles, visible foreign matter, clarity, related substances and labeling Contents and packaging materials for direct contact with pharmaceuticals
- the internal and external surface properties of brown borosilicate glass controlled injection bottles and medicinal butyl rubber stoppers were investigated. Compared with the 0-day samples, the experimental results are as follows:
- the chlorogenic acid for injection is prepared into a test solution according to the maximum concentration (0. 03%) of the clinical application, respectively, by adding 0.9% sodium chloride injection, 5% glucose injection and water for injection, at 0, 2 Samples were taken at 4 and 6 hours to check the color, PH value, clarity, insoluble particles, visible foreign matter, related substances and labeled content of each test solution. The inspection results are shown in Table 15.
- the results of the study showed that the chlorogenic acid for injection was prepared into the clinically-used maximum concentration solution by using the commonly used 0.9% sodium chloride injection, 5% glucose injection and water for injection, and the content did not change significantly within 6 hours; The solution is clear and colorless; the insoluble particles and visible foreign matter are qualified; the relevant substances have no obvious change, indicating that the chlorogenic acid for injection has good stability with the commonly used injection solvent. In order to ensure the quality and safety of chlorogenic acid, it is recommended that the preparation solution should be used within 6 hours during clinical use.
- the inventors screened the antioxidant, the optimum pH, the amount of activated carbon, the adsorption method, and the scaffold used for lyophilization. The result was sodium bisulfite.
- the pH of the chlorogenic acid solution is controlled to be 2 to 4 in the preparation, which is favorable for the stability of the preparation; and 0.03% of activated carbon is stirred at 45 ° C to 50 ° C for 30 minutes to filter, the loss rate of chlorogenic acid It is about 5%, and the pyrogen (endotoxin) is qualified; the lyophilized product obtained by using 4% mannitol as a preparation scaffold has good moldability and good resolubility; the process verification results prove the rationality of the prescription and the process; Seven batches of products were produced. After all inspections, the quality indicators of the seven batches of products were in compliance with the regulations, which fully proved the rationality of the prescriptions and processes.
- the experimental results of the product influencing factors indicate that the chlorogenic acid for injection should be stored in the cool and dark places; the quality research and stability study results of the product further prove the rationality of the prescription and the process; the stability study of the product is carried out, and the injection is used.
- the stability of chlorogenic acid and the commonly used injectable solvent within 6 hours is good. It is recommended that the preparation solution should be used within 6 hours during clinical use.
- the chlorogenic acid powder injection of the invention has good stability, strong resolubility, safe clinical use, and has excellent clinical application and industrialization prospects.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/911,100 US9918956B2 (en) | 2013-08-21 | 2013-08-21 | Chlorogenic acid powder-injection and preparation method thereof |
JP2016535291A JP2016528261A (ja) | 2013-08-21 | 2013-08-21 | クロロゲン酸粉末注射剤及びその製造方法 |
EP13891994.9A EP3040067A4 (en) | 2013-08-21 | 2013-08-21 | Chlorogenic acid powder-injection and preparation method thereof |
PCT/CN2013/081967 WO2015024217A1 (zh) | 2013-08-21 | 2013-08-21 | 一种绿原酸粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/081967 WO2015024217A1 (zh) | 2013-08-21 | 2013-08-21 | 一种绿原酸粉针剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015024217A1 true WO2015024217A1 (zh) | 2015-02-26 |
Family
ID=52482955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/081967 WO2015024217A1 (zh) | 2013-08-21 | 2013-08-21 | 一种绿原酸粉针剂及其制备方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9918956B2 (zh) |
EP (1) | EP3040067A4 (zh) |
JP (1) | JP2016528261A (zh) |
WO (1) | WO2015024217A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431083A4 (en) * | 2016-03-15 | 2019-11-13 | Sichuan Jiuzhang Bio-technology Co., Ltd. | USE OF CHLOROGENIC ACID IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LAG-3-MEDIATED ILLNESSES |
CN116218236A (zh) * | 2022-12-20 | 2023-06-06 | 西北农林科技大学 | 一种基于绿原酸纳米颗粒的功能性食品包装膜 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352457A (zh) * | 2014-11-24 | 2015-02-18 | 四川九章生物科技有限公司 | 一种包含绿原酸晶型的制剂及其用途 |
CN107952064B (zh) * | 2016-10-14 | 2023-10-20 | 江苏豪森药业集团有限公司 | 含有聚乙二醇洛塞那肽的药物制剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1568960A (zh) * | 2004-05-08 | 2005-01-26 | 四川九章生物化工科技发展有限公司 | 高纯度绿原酸制剂 |
CN1616403A (zh) * | 2004-09-21 | 2005-05-18 | 济南永曜医药科技有限公司 | 从金银花中提取制备绿原酸的工艺 |
CN1813705A (zh) * | 2005-11-23 | 2006-08-09 | 广东大光药业有限公司 | 一种注射用绿原酸粉针剂及其制备方法及其用途 |
CN102391119A (zh) * | 2011-11-14 | 2012-03-28 | 肖文辉 | 高纯度绿原酸制剂的制备及临床应用 |
-
2013
- 2013-08-21 US US14/911,100 patent/US9918956B2/en active Active
- 2013-08-21 JP JP2016535291A patent/JP2016528261A/ja active Pending
- 2013-08-21 WO PCT/CN2013/081967 patent/WO2015024217A1/zh active Application Filing
- 2013-08-21 EP EP13891994.9A patent/EP3040067A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1568960A (zh) * | 2004-05-08 | 2005-01-26 | 四川九章生物化工科技发展有限公司 | 高纯度绿原酸制剂 |
CN1616403A (zh) * | 2004-09-21 | 2005-05-18 | 济南永曜医药科技有限公司 | 从金银花中提取制备绿原酸的工艺 |
CN1813705A (zh) * | 2005-11-23 | 2006-08-09 | 广东大光药业有限公司 | 一种注射用绿原酸粉针剂及其制备方法及其用途 |
CN102391119A (zh) * | 2011-11-14 | 2012-03-28 | 肖文辉 | 高纯度绿原酸制剂的制备及临床应用 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431083A4 (en) * | 2016-03-15 | 2019-11-13 | Sichuan Jiuzhang Bio-technology Co., Ltd. | USE OF CHLOROGENIC ACID IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LAG-3-MEDIATED ILLNESSES |
CN116218236A (zh) * | 2022-12-20 | 2023-06-06 | 西北农林科技大学 | 一种基于绿原酸纳米颗粒的功能性食品包装膜 |
CN116218236B (zh) * | 2022-12-20 | 2024-03-15 | 西北农林科技大学 | 一种基于绿原酸纳米颗粒的功能性食品包装膜 |
Also Published As
Publication number | Publication date |
---|---|
US20160193176A1 (en) | 2016-07-07 |
JP2016528261A (ja) | 2016-09-15 |
US9918956B2 (en) | 2018-03-20 |
EP3040067A4 (en) | 2017-03-22 |
EP3040067A1 (en) | 2016-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108938626B (zh) | 一种稳定性好和安全性高的卡络磺钠药物组合物及其制备方法和应用 | |
AU2017422167A1 (en) | Preparation of Pulsatilla saponin B4 for injection | |
WO2015024217A1 (zh) | 一种绿原酸粉针剂及其制备方法 | |
CN102302463A (zh) | 注射用兰索拉唑冻干粉针剂及制备方法 | |
KR101468153B1 (ko) | 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법 | |
WO2005004874A1 (fr) | Preparation medicinale lyophilisee stable contenant de la tetrodotoxine | |
CN103446064B (zh) | 一种绿原酸粉针剂及其制备方法 | |
CN102113994A (zh) | 一种脑血管扩张药及其制备方法 | |
CN104257615A (zh) | 一种地佐辛冻干药物组合物及其制备方法 | |
WO2016045530A1 (zh) | 一种高复溶性及高稳定性的绿原酸冻干粉针 | |
CN103055305B (zh) | 一种注射用含细胞色素c药物组合物的冻干制剂、制备方法 | |
CN103860483A (zh) | 复方甘草酸苷类冻干粉针注射剂及其制备方法 | |
CN103494779B (zh) | 一种注射用炎琥宁粉针制剂及其制备方法 | |
CN114159396A (zh) | 一种注射用艾司奥美拉唑钠冻干制剂及其制备方法 | |
CN109984998B (zh) | 注射用奥美拉唑钠的制备方法 | |
CN104800172B (zh) | 注射用卡络磺钠粉针剂和制法 | |
CN109758423B (zh) | 使用维生素k1脂肪乳注射液治疗凝血功能障碍的方法 | |
CN108309944B (zh) | 注射用泮托拉唑钠及其制备方法 | |
CN109200022B (zh) | 一种注射用托拉塞米及其制备工艺 | |
CN112043674A (zh) | 一种注射用七叶皂苷钠冻干制剂及其制备方法 | |
CN103462907A (zh) | 一种注射用奥美拉唑钠冻干粉针剂及其制备方法 | |
CN105496954A (zh) | 一种肌松药物罗库溴铵的注射液的制备方法 | |
CN101491495A (zh) | 丹酚酸b镁注射剂、制备方法及应用 | |
CN107536808B (zh) | 一种米铂冻干制剂及其制备方法 | |
CN103462908A (zh) | 一种注射用雷贝拉唑钠冻干粉针剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13891994 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016535291 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14911100 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013891994 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013891994 Country of ref document: EP |